ArticleESMO open2026

First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies.

V Ekström-Rydén et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.